Skip to main content
Displaying 13 - 24 of 39
Display:
12
24
48
Liver Tumours
5
Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020
View
Liver Tumours
5
Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020
View
Liver Tumours
5
Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020
View
Viral Hepatitis
4
AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020
View
Viral Hepatitis
4
AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020
View
Viral Hepatitis
4
AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020
View
Viral Hepatitis
4
AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020
View
Immune-Mediated and Cholestatic Diseases
1
Albireo: Challenges in the Management of Patients with Cholestatic Liver Diseases - Digital ILC 2020
View
Metabolism, Alcohol & Toxicity
4
Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020
View
Metabolism, Alcohol & Toxicity
4
Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020
View
Metabolism, Alcohol & Toxicity
4
Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020
View
Metabolism, Alcohol & Toxicity
4
Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020
View
Pagination
First page
« First
Previous page
‹ previous
Page
1
Current page
2
Page
3
Page
4
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy